Patents by Inventor Olle Hernell
Olle Hernell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230248043Abstract: A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.Type: ApplicationFiled: April 14, 2023Publication date: August 10, 2023Inventors: Bo Lönnerdal, Olle Hernell, Lars-Börje Sjöberg, Catharina Tennefors
-
Patent number: 11647777Abstract: A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.Type: GrantFiled: August 23, 2016Date of Patent: May 16, 2023Assignee: Semper ABInventors: Bo Lönnerdal, Olle Hernell, Lars-Börje Sjöberg, Catharina Tennefors
-
Publication number: 20220267469Abstract: The present invention relates to novel isolated antibodies and antigen-binding fragments thereof that bind to human Bile Salt-Stimulated Lipase (hBSSL). The antibodies and antigen-binding fragments thereof bind to a previously uncharacterized epitope, situated in the N-terminal part of hBSSL and identified as comprising the amino acid residues 7-12 and the amino acid residues 42-55. The 5 present invention also relates to the medical uses of the antibodies and/or the antigen-binding fragments thereof, in particular in treatment of inflammatory conditions, and to related pharmaceutical compositions.Type: ApplicationFiled: July 10, 2020Publication date: August 25, 2022Inventors: Olle HERNELL, Susanne LINDQUIST, Lennart LUNDBERG, Helena PERSSON LOTSHOLM
-
Publication number: 20200291136Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: May 29, 2020Publication date: September 17, 2020Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Patent number: 9889162Abstract: The present invention concerns the field of nutritional compositions and concerns a nutritional composition, especially an infant formula containing whey protein/milk protein concentrate solids rich in phospholipids, rich in MFGM for use in the prophylaxis and prevention of infectious morbidity, especially otitis. At the same time the use of antipyretics has diminished.Type: GrantFiled: June 26, 2014Date of Patent: February 13, 2018Assignee: HERO AGInventors: Bo Lönnerdal, Olle Hernell, Lars-Börje Sjöberg, Catharina Tennefors
-
Publication number: 20170013869Abstract: A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.Type: ApplicationFiled: August 23, 2016Publication date: January 19, 2017Applicant: HERO AGInventors: Bo LÖNNERDAL, Olle HERNELL, Lars-Börje SJÖBERG, Catharina TENNEFORS
-
Publication number: 20160158287Abstract: The present invention concerns the field of nutritional compositions and concerns a nutritional composition, especially an infant formula containing whey protein/milk protein concentrate solids rich in phospholipids, rich in MFGM for use in the prophylaxis and prevention of infectious morbidity, especially otitis. At the same time the use of antipyretics has diminished.Type: ApplicationFiled: June 26, 2014Publication date: June 9, 2016Inventors: Bo LÖNNERDAL, Olle HERNELL, Lars-Börje SJÖBERG, Catharina TENNEFORS
-
Publication number: 20160096899Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: September 28, 2015Publication date: April 7, 2016Inventors: OLLE HERNELL, SUSANNE LINDQUIST, LENNART GUSTAV LUNDBERG
-
Patent number: 9168299Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: GrantFiled: October 30, 2013Date of Patent: October 27, 2015Assignee: LIPUM ABInventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Publication number: 20150297683Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: March 12, 2015Publication date: October 22, 2015Inventors: Olle HERNELL, Birgitta OLSSON, Patrik STROMBERG, Lennart SVENSSON, Kristina TIMDAHL, Marten VAGERO, Maria OHMAN
-
Publication number: 20150283215Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: March 12, 2015Publication date: October 8, 2015Inventors: Olle HERNELL, Birgitta OLSSON, Patrik STROMBERG, Lennart SVENSSON, Kristina TIMDAHL, Marten VAGERO, Maria OHMAN
-
Patent number: 8986682Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: GrantFiled: October 21, 2011Date of Patent: March 24, 2015Assignee: Swedish Orphan Biovitrum AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Patent number: 8986759Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: GrantFiled: October 21, 2011Date of Patent: March 24, 2015Assignee: Swedish Orphan Biovitrum AB (pub)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, M{hacek over (a)}rten Vågerö, Maria Öhman
-
Publication number: 20150079225Abstract: A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.Type: ApplicationFiled: April 9, 2013Publication date: March 19, 2015Inventors: Bo Lönnerdal, Olle Hernell, Lars-Börje Sjöberg, Catharina Tennefors
-
Publication number: 20140099323Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: October 30, 2013Publication date: April 10, 2014Inventors: OLLE HERNELL, SUSANNE LINDQUIST, LENNART GUSTAV LUNDBERG
-
Patent number: 8597650Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: GrantFiled: April 6, 2010Date of Patent: December 3, 2013Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Publication number: 20120100127Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Publication number: 20120100126Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Publication number: 20120093829Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: April 6, 2010Publication date: April 19, 2012Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Patent number: 6232094Abstract: The present invention relates to an expression system comprising a DNA sequence encoding a polypeptide which has a biological activity of human &kgr;-casein, the system comprising a 5′-flanking sequence capable of mediating expression of said DNA sequence. In preferred embodiments the 5′-flanking sequence is from a milk protein gene of a mammal such as a casein gene or whey acidic protein (WAP) gene and the DNA sequence contains at least one intron sequence selected from the intron sequences presented in SEQ ID NO:30. The invention also relates to DNA sequences, replicable expression vectors and cells harboring said vectors, recombinant polypeptide e.g. in glycosylated form, and milk, infant formula or nutrient supplement comprising recombinant polypeptide.Type: GrantFiled: June 5, 1995Date of Patent: May 15, 2001Assignee: Symbicom AktiebolagInventors: Lennart Hansson, Mats Strömqvist, Sven Bergström, Olle Hernell, Jan Törnell